Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at Cantor’s 2026 Global Healthcare Conference, scheduled for Sept. 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., will present on Sept. 10 from 3:55-4:25 p.m. ET. A live webcast and replay will be available through the Investors section of the Tonix website.
Tonix is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company’s flagship medicine, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved as the first new treatment for fibromyalgia in more than 15 years. This approval marks a significant milestone for patients suffering from this chronic condition, offering a new therapeutic option where few have existed.
Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. The company is also maximizing the science behind TONMYA by conducting Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. These conditions represent substantial unmet needs, and positive results could expand TONMYA’s indications significantly.
In addition, Tonix’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare genetic disorder. The company is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These programs highlight Tonix’s commitment to addressing serious conditions with limited treatment options.
The participation of Tonix’s management at the Cantor conference provides an opportunity for investors and industry stakeholders to gain insights into the company’s strategic direction and pipeline progress. The fireside chat and one-on-one meetings will allow for in-depth discussions about the company’s recent achievements and future plans.
This news is important as it underscores Tonix’s active engagement with the investment community and its continued efforts to advance its diverse pipeline. The presentation at a major healthcare conference signals the company’s confidence in its programs and its commitment to transparency. For patients, the ongoing development of TONMYA for additional indications and the advancement of other CNS and immunology candidates could eventually lead to new treatments that address significant unmet medical needs.
Investors and interested parties can access the live webcast and replay through the Investors section of the Tonix website. The latest news and updates relating to TNXP are available in the company’s newsroom at https://nnw.fm/TNXP. For more information about Tonix Pharmaceuticals, visit the company’s website. The full press release is available at https://nnw.fm/hajiz.
